New weight loss shot CPX101 enters early human testing

NCT ID NCT06545162

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new injectable drug called CPX101 in 72 healthy volunteers and overweight or obese patients. The main goal was to check safety and how the body processes the drug, with a preliminary look at weight loss. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CPX101 (a biologic drug given by injection)

What this could lead to

If it works, this could lead to a new injectable medication for weight loss in people who are overweight or obese.

What could go wrong

This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not cause significant weight loss or could have side effects. Results may not apply to the general population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, 100000, China

  • Beijing Luhe hospital

    Beijing, Beijing Municipality, 100000, China

  • Beijing hospital

    Beijing, Beijing Municipality, 100000, China